Imunon’s (IMNN) “Buy” Rating Reiterated at HC Wainwright

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $14.00 price target on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $29.00 price target on shares of Imunon in a research report on Monday.

Imunon Stock Down 6.1 %

Shares of NASDAQ:IMNN opened at $1.00 on Wednesday. The company’s fifty day moving average is $0.90 and its 200 day moving average is $0.91. Imunon has a 52 week low of $0.64 and a 52 week high of $3.65. The stock has a market cap of $14.62 million, a PE ratio of -0.53 and a beta of 1.96.

Institutional Investors Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC grew its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the period. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 as of its most recent SEC filing. 4.47% of the stock is owned by institutional investors and hedge funds.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.